## Athena Pharmaceutiques acquired Medipha Santé

## June 3rd, 2025:

Athena Pharmaceutiques SA France, a leading innovator in the pharmaceutical industry, is thrilled to announce the acquisition of Medipha Santé, expert in pharmaceutical commercialization, regulatory affairs and pharmacovigilance.

This operation is part of Athena Pharmaceutiques' plan to strengthen its expertise and presence on the drug delivery market, and broaden its service offering in regulatory management, becoming a full service platform capable of developing, producing and marketing around the world.

Together, Athena and Medipha will continue to support Pharmaceutical partners with a more complete set of services while maintaining a strong focus on quality and local know-how.

This step reinforces the commitment to provide reliable, efficient and compliant pharmaceutical solutions to all partners.

## **About Athena:**

Athena is engaged in Licensing and Development model supported by its Manufacturing facilities and R&D Centre in France and India approved by EU GMP, Brazil, Canada, Russia, KSA, China and many others Pharmemerging markets. Athena's 450 Specialized Staff are focus on value added products for mature and emerging markets.

Athena provides product lifecycle management solutions for Oral Solids based on its proprietary technology's platforms viz., Acetyl Cysteine Stick w/wo water, Bisoprolol Aspirin, Bilastine ODT, Etifoxine, Fenofibrate, Levoceterizine ODT, Ketorolac Sublingual, Ketoprofen-Omeprazole, Lisdexamphetamine ODT, Mesalasine High Dose Sachets, Ondansetron ODT, Paracetamol Effervescent Tablet, Secnidazole High Dose Sachet, Racecadotril Sachets, Tramadol +Paracetamol ODT and Zolpidem ODT and Sublingual. These products are already marketed by leading companies across geographies or are under registration.

## **About Medipha:**

For more than 20 years, Medipha has been guiding pharmaceutical laboratories and distributors through registering, commercializing, distributing to cities and hospitals, and monitoring drugs in the patients' service.

Medipha's status of operator and importer is key to offering a wide range of services such as regulatory strategy, pharmacovigilance or Market Access.